EAN 2026: Bocunebart’s promise as migraine preventive in treatment-refractory patients
On 29 June, at the 12th Congress of the European Academy of Neurology (EAN) 2026, as part of a late-breaking …
Post
-
-
QuantumCell commits $2.2bn on AlzeCure’s Alzheimer’s platform
Less than a year after emerging from stealth, Danish-based QuantumCell has signed a multi-billion-dollar deal to equip its pipeline with …
-
Sanofi aims for Nexviazyme approval in younger Pompe disease patients
Sanofi’s Nexviazyme (avalglucosidase alfa) could be set for approval in younger children with Pompe disease after the Phase III Baby-COMET …
-
Surge in RMAT designations awarded by the FDA
Since the first time the US Food and Drug Administration (FDA) awarded a regenerative medicine advanced therapeutic (RMAT) designation in …
-
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which was …
-
Anthropic debuts AI-driven pharma R&D tool, Claude Science
Tech giant Anthropic has extended its foray into the life sciences space with a new artificial intelligence (AI) tool, Claude …
-
Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown
In another blow to the future market prospects of Amgen’s rare disease therapy, Tavneos (avacopan), the New England Journal of …
-
US FDA rejects approval of Unicycive’s kidney disease therapy
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate …
-
EAN 2026: following EU approval, AbbVie highlights Aquipta efficacy for acute migraine
On June 27, at the 12th Congress of the European Academy of Neurology (EAN) 2026, three e-posters with results from …
-
Beyond the GLP-1RA weight loss ceiling
On 21 May 21, 2026, Eli Lilly’s retatrutide achieved a historic first; as of June 2026, it is the only …
-
Eli Lilly and Innovent agree Verzenios commercialisation deal in China
Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland …
-
EAN 2026: New Fintepla data in Dravet Syndrome and LGS
Researchers at the Brno Epilepsy Centre in Czechia announced data from a retrospective, single-centre observational study evaluating the efficacy and …
-
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
Eli Lilly and Regeneron are in the first slate of drugmakers included in a new US scheme to expedite the …
-
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
New Jersey-based biotech, Talawar Therapeutics and JATT II Acquisition have joined forces through a definitive business combination agreement – creating …
-
Anixa Biosciences secures Korean patent for breast cancer vaccine
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology. The …
